P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

NCT06468033 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Myeloproliferative Neoplasm

Interventions

BIOLOGICAL: Ropeginterferon alfa-2b
OTHER: Placebo

Sponsor

PharmaEssentia